Epigenetic Therapy for Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byEdwin Posadas, MD

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Edwin Posadas, MD

No Placebo Group

Trial Summary

What is the purpose of this trial?This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.

Eligibility Criteria

This trial is for men with localized prostate cancer who are scheduled for radical prostatectomy. Participants should be interested in trying a treatment that may make their immune system better at attacking the tumor.

Inclusion Criteria

I am a man choosing to have surgery to remove my prostate and have tissue samples available from before the surgery.

I am 18 years old or older.

Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

+3 more

Exclusion Criteria

I have another illness or cancer that needs treatment besides prostate cancer.

I have not had recent cancer treatments like chemotherapy or surgery.

Currently participating in a study using an investigational, medicinal anti-cancer agent within 4 weeks prior to the first dose of epigenetic therapy

Participant Groups

The study is testing epigenetic therapy given before surgery to see if it's safe and can help the body fight prostate cancer more effectively. It's an open-label, non-randomized trial focusing on how well this therapy works and its effects on certain biomarkers.

1Treatment groups

Experimental Treatment

Group I: Neoadjuvant Epigenetic TherapyExperimental Treatment1 Intervention